Global generic drugs market to reach $671.5B by 2030, report finds
The global market for generic drugs estimated at $430.2 billion in 2023, is projected to reach a revised size of $671.5 billion by 2030, growing at a CAGR of 5.7% over the analysis period 2023-2030, per ResearchAndMarkets.com's “The "Generic Drugs - Global Strategic Business Report."
The global economic update coincides with a rising demand for generic painkillers, reflecting the growing significance of generic drugs in the pharmaceutical market. Competition among key players is highlighted, with market share percentages and competitive market presence outlined for 2023. Despite promising opportunities, sustaining success in this market requires strategic approaches. Challenges such as pricing dynamics and accessibility persist, but recent market activity suggests ongoing developments in response to these challenges, per the report
Small-molecule generics, one of the segments analyzed in the report, is projected to record 4.2% CAGR and reach $538.8 billion by the end of the analysis period. Growth in the biosimilars segment is estimated at 15.3% CAGR for the next 8-year period.
[Read more: Challenges continue, but generics companies see a bright future with] biosimilars]
The U.S. market is estimated at $130.2 billion, while China is forecast to Grow at 7.1% CAGR.
Both North America and Europe are key players in this sector, while the Asia-Pacific region emerges as a hotspot for rapid growth. India stands out as a significant market, particularly for small-molecule generic drugs, although biosimilars also are experiencing notable growth.
The generic drugs market in the U.S. is estimated at $130.2 billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of $126.8 billion by the year 2030 trailing a CAGR of 7.1% over the analysis period 2023 to 2030.
Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.2% and 5% respectively over the 2023-2030 period. Within Europe, Germany is forecast to grow at approximately 4.9% CAGR.
[Read more: Avalere analysis examines Medicare Part D’s plan tier placement of generics]